Article
Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm.
Blood advances - 11 Jun 2024
Bataller Alex, Gener-Ricos Georgina, Almanza-Huante Emmanuel, Chien Kelly S, Urrutia Samuel, Bazinet Alexandre, Rodriguez-Sevilla Juan Jose, Hammond Danielle, Sasaki Koji, Takahashi Koichi, DiNardo Courtney D, Ravandi Farhad, Borthakur Gautam, Kadia Tapan M, Kanagal-Shamanna Rashmi, Kantarjian Hagop M, Garcia-Manero Guillermo, Montalban-Bravo Guillermo
Abstract excerpt
ABSTRACT: Therapy-related myeloid neoplasms (t-MNs) arise after exposure to cytotoxic therapies and are associated with high-risk genetic features and poor outcomes. We analyzed a cohort of patients with therapy-related chronic myelomonocytic leukemia (tCMML; n = 71) and compared its features to that of de novo CMML (dnCMML; n = 461). Median time from cytotoxic therapy to tCMML diagnosis was 6.5 years. Compared...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.